Skip to main content

Results from a recent chemoprevention trial indicate that the Bowman-Birk inhibitor concentrate (BBIC), a protease inhibitor derived from soybeans, can help shrink oral leukoplakia, which are abnormal growths in the mouth that can lead to oral cancer.

Oral cancer is characterized by the presence of cancer cells in the mouth and/or the lips. Individuals who use chewing tobacco, smoke pipes, or have long-term sun exposure have a higher risk of developing oral cancer. Sometimes, leukoplakia in the mouth can signal the early stages of oral cancer. Leukoplakia are raised white patches in the oral cavity that do not rub off. Leukoplakia can be caused by a heaped up surface layer of normal cells (hyperkeratosis) or an actual early invasive carcinoma or may represent only a fungal infection, lichen planus, or other benign oral disease.

The Bowman-Birk inhibitor is a protease inhibitor derived from soybeans that has demonstrated chemopreventive activity. During this clinical study, a Bowman-Birk inhibitor concentrate (BBIC) was administered to 32 patients with oral leukoplakia. The 32 patients were divided among four groups receiving differing doses. The patients received the BBIC twice daily for one month. The BBIC was dispensed as a powder suspended in liquid. Patients held this suspension in their mouths for one minute before swallowing it.

After one month of treatment with BBIC, 31% of patients experienced a partial or complete response to treatment. On average, there was a 24% decrease in the size of the leukoplakia. Furthermore, in 10 of the 32 patients, the leukoplakia shrunk by 50%. The researchers noted that the higher doses of BBIC produced the most significant results. No side effects were observed.

Recommended Articles


Do Your Part to Aid in the Fight Against Cancer

Cancer is a leading cause of death in the United States and throughout the world.

Sarcoma News & Updates

Fyarro for Malignant Perivascular Epithelioid Cell Tumor (PEComa)

The U.S. Food and Drug Administration (FDA) has approved FYARRO™ (sirolimus protein-bound particles for injectable suspension) (albumin-bound) for intravenous use for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

Image placeholder title

CAR-T Cell Therapy - Advances in The Management of Multiple Myeloma

FDA Approves CAR T-cell therapy for multiple myeloma, ASH 2021 update.

The dose-dependent decrease in oral leukoplakia with the use of BBIC, as well as the absence of side effects, suggests that BBIC may be a promising chemopreventive agent in patients with oral leukoplakia. More research is necessary to further define the role of BBIC in the prevention of oral cancer.

Individuals with oral leukoplakia and/or who may be at a high-risk for developing oral cancer may wish to speak with their physicians about the risks and benefits of participating in a clinical trial in which BBIC and other promising new chemopreventive agents are being evaluated. (

Clinical Cancer Research, Vol 6, pp. 4684-4691, 2000)

Copyright © 2018 CancerConnect. All Rights Reserved.